Расширенный поиск

Иммунотерапия метастатического почечно-клеточного рака

Полный текст:

Об авторах

Л. Геман
Department of Urology, Leuven

С. Жоньо
Department of Urology, Leuven

Х. ван Поппель
Department of Urology, Leuven

Список литературы

1. Hock L.M., Lynch J., Balaji K.C. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data // J. Urol. — 2002; 167: 57—60.

2. Negrier S., Maral J., Drevon et al. Long term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant IL-2 in Europe // Cancer J. Sci. Am. — 2000; 6(suppl 1): 93—98.

3. Law T.M., Motzer R.J., Mazumdar M. et al. Phase III randomized trial of IL-2 with or without LAK cells in the treatment of patients with advanced renal cell carcinoma // Cancer. — 1995; 76: 824—832.

4. Lee D.S., White D.E, Hurst R. et al. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to IL-2-based immunotherapy // Cancer J. Sci. Am. — 1998; 4: 86—93.

5. Fisher R.I., Rosenberg S.A., Fyfe G. et al. Longterm survival update for high-dose recombinant IL-2 in patients with renal cell carcinoma // Cancer J. Sci. Am. — 2000; 6 (suppl 1): 55—57.

6. Ulchaker J., Panuto J., Rayman P. et al. IF-gamma production by T-lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to IL-12 // J. Immunother. — 1999; 22: 71—79.

7. Kudoh S., Redovan C., Rayman P. et al. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma // J. Immunother. — 1997; 20: 479—487.

8. Lauerova L., Dusek L., Simickova M. et al. Renal cell carcinoma –associated immune impairment that may interfere with the response to cytokine therapy // Neoplasma. — 1999; 46: 141—149.

9. Almand B., Clark J.I., Nikitina E. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppresion in cancer // J. Immunol. — 2001; 166: 678—689.

10. Tso C.I., Zisman A., Pantuck A. et al. Induction of G 250-targeted and T-cell mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and GM-CSF // Cancer. Res. — 2001; 61: 7925—7933.

11. Patel N.P., Lavengood R.W. Renal cell carcinoma; natural history and results of treatment // J. Urol. — 1978; 199: 722—726.

12. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma // N. Engl. J. Med. — 1996; 335: 865—875.

13. Piltz S., Meimarakis G., Wichmann M.W. et al. Long-term results after pulmonary resection of renal cell carcinoma metastases // Ann. Thorac. Surg. — 2002; 73: 1082—1087.

14. Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2f alone for metastatic renal cell cancer // N. Engl. J. Med. — 2001; 345: 1655—1659.

15. Mickisch G.H., Garin A., Van Poppel H. et al. Radical nephrectomy plus IF-alfa based immunotherapy compared with IF-alfa alone in metastatic renal cell carcinoma: a randomised trial // Lancet. — 2001; 358: 966—970.

16. Motzer R.J., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma // J. Clin. Oncol. — 1999; 17: 2530—2540.

17. Zisman A., Pantuck A.J., Dorey F. et al. Mathematical Model to predict individual survival for patients with renal cell carcinoma // J. Clin. Oncol. — 2002; 1368—1374.

18. Naitoh J., Kaplan A., Dorey F. et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy // J. Urol. 1999; 162: 46—50.

19. Walther M.M., Lyne J.C., Libutti S.K. et al. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic IL-2 in the treatment of metastatic renal cell carcinoma: a pilot study // Urology. — 1999; 53: 496—501.

20. Wagner J.R., Walther M.M., Linehan W.M. et al. IL-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. // J. Urol. — 1999; 162: 43—45.

21. Whitney R.B., Levy J.G., Smith A.G. Influence of tumor size and surgical resection on cell-mediated immunity in mice // J. Natl. Cancer. Inst. — 1974; 53: 111—116.

22. Musselman D.L., Lawson D.H., Gummick J.F. et al. Paroxetine for the prevention of depression induced by high-dose interferon-alfa // N. Engl. J. Med. — 2001; 344: 961—966.

23. Schwartzentruber D.J. Guidelines for the safe administration of high-dose IL-2 // J. Immunother. — 2001; 24: 287—293.

24. Hoffman D., Gitlitz B., Moldawer N. et al. High dose bolus IL-2 in a non-intensive care unit setting for metastatic renal cell carcinoma: UCLA Kidney Cancer Program // Proc. Annu Meet Am. Soc. Clin. Oncol. — 2000; 1357 Abstract.

25. Negrier S., Escudier B., Lasset C. et al. Recombinant human IL-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie // N. Engl. J. Med. — 1998; 338 :1272—1278.

26. Weiss G.R., Margolin K.A., Aronson F.R. et al. A randomized phase II trial of continous infusion IL-2 or bolus injection IL-2 plus LAK for advanced renal cell carcinoma // J. Clin. Oncol. — 1992; 10: 275—281.

27. Ier S., Caty A., Lesimple T. et al. Treatment of patients with metastatic renal cell carcinoma with a combination of subcutaneous IL-2 and IF-alfa with or without fluoro-uracil. Groupe Francais d’Immunotherapie. Federation Nationale des Centres de Lutte Contre Le cancer // J. Clin. Oncol. — 2000; 18 : 4009—4015.

28. Atzpodien J., Kirchner H., Illiger H.J. et al. IL-2 in combination with IF-alfa and 5-FU versus Tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomised clinical trial // Br. J. Cancer. — 2001; 85:1130—1136.

29. Fossa S.D. Interferon in metastatic renal cell carcinoma // Semin. Oncol. — 2000; 27: 187—193.

30. Pfeffer L.m., Wang C., Constantinescy S.N. et al. Human renal cancers resistant to IFN’s antiproliferative action exhibit sensitivity to IFN’s gene-inducing and antiviral actions // J. Urol. 1996; 156: 1867—1871.

31. Albini A., Marchisone C., Del Grosso F. et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach // Am. J. Pathol. — 2000; 156: 1381—1393.

32. Motzer R.J., Mazumdar M., Bacik J. et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. // J. Clin. Oncol. — 2000; 18: 1928—1935.

33. Pizzocaro G., Piva L., Colavita M. et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomised study // J. Сlin. Oncol. — 2001; 19: 422—4231.

34. Henriksson R., Nilsson S., Colleen S. et al. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs IL-2, IFN-alfa (Leucocyte) and tamoxifen // Br. J. Cancer . — 1998; 77: 1311—1317.

35. Daniels G.A., Galanis E. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex // Curr. Opin. Mol. Ther. — 2001; 3: 70—76.

36. Motzer R.J., Rakhit A., Ginsberg M. et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma // J. Clin. Oncol. — 2001; 19: 1312—1319.

37. Yang J.C., Topalian S.L., Schwartzentruber D.J. et al. The use of polyethylene glycol-modified IL-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2 // Cancer. — 1995; 76: 687—694.

38. Kedar E., Gur H. Babai I. et al. Delivery of cytokines by liposomes; hematopoietic and immunomodulatory activity of IL-2 encapsulated in conventional liposomes and in long-circulating liposomes // J. Immunother. 2000; 23: 131—145.

39. Shanafelt A.B., Lin Y., Shanafelt M.C. et al. A T-cell selective IL-2 mutein exhibits potent antitumor activity and is well tolerated in vivo // Nat. Biotechnol. — 2000; 18: 1197—1202.

40. Schwaab T., Heaney J.A., Schned A.R. et al. A randomised phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon-gamma and human recombinant alpha-2b therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters // J. Urol. — 2000; 163: 1322—1327.

41. Tate J., Olencki T., Finke J. et al. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal cell carcinoma: clinical and laboratory effects // Ann. Oncol. — 2001; 12: 655—659.

42. Fishman M., Seigne J., Antonia S. Novel therapies for renal cell carcinoma // Expert Opin. Investig. Drugs. — 2001; 10 : 1033—1044.

43. Jiang F., Desper R., Papadimitriou C.H. et al. Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridisation data // Cancer Res. — 2000; 60: 6503—6509.

44. Caudill M.M., Li Z. HSPPC-96: a personalised cancer vaccine // Expert. Opin. Biol. Ther. — 2001; 1: 539—547.

45. Antonia S.J., Seigne J., Diaz J. et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic IL-2 in patients with metastatic renal cell carci-noma // J. Urol. 2002; 167: 1995—2000.

46. Wiseman G.A., Scott A.M., Lee F-T. et al. Chimeric G250 (cG250) monoclonal antibody Phase I dose escalation trial in patients with advanced renal cell carcinoma (RCC) // Proc. Annu. Meet. Am. Soc. Clin. Oncol. — 2001; 1027. Abstract.

47. Schwartz G., Dutcher J.P., Vogelzang N.J. et al. Phase II clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC) // Proc. Annu. Meet. Am. Soc. Clin. Oncol. — 2002; 91. Abstract.

48. Yang J.C., Haworth L., Steinberg S.M. et al. A randomized double-blind placebo controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer // Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002; 15.

49. Holden S.A., Lan Y., Pardo A.M. et al. Augmentation of antitumor activity of an antibody-IL-2 immunocytokine with chemotherapeutic agents // Clin. Cancer. Res. — 2001; 7: 2862—2869.

50. Carnemolla B., Borsi L., Balza E. et al. Enhancement of the antitumor properties of IL-2 by its targeted delivery to the tumor blood vessel extracellular matrix // Blood. — 2002; 99: 1659—1665.

51. Figlin R.A., Thompson J.A., Bukowski R.M. et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymhocytes in combination with recombinant IL-2 in metastatic renal cell carcinoma // J. Сlin. Oncol. 1999; 17: 2521—2529.

52. Rosenberg S.A., Lotze M.T., Yang J.C. et al. Prospective randomised trial of high-dose IL-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer //J. Natl. Cancer. Inst. — 1993; 85: 622—632.

53. Childs R., Chernoff A., Contentin N. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation // N. Engl. J. Med. — 2000; 343:750—758.

54. Rini B.I., Zimmerman T., Stadler W.M. et al. Allogeneic stemcell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results // J. Clin. Oncol. — 2002; 20: 2017—2024.v

Для цитирования:

Геман Л., Жоньо С., ван Поппель Х. Иммунотерапия метастатического почечно-клеточного рака. Онкоурология. 2005;1(3):16-21.

For citation:

Goeman L., Joniau S., Van Poppel H. The use of immunotherapy for metastatic renal cell carcinoma. Cancer Urology. 2005;1(3):16-21. (In Russ.)

Просмотров: 7

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)